CoChat

Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

Thriemer, Kamala, Degaga, Tamiru Shibru, Christian, Michael, Alam, Mohammad Shafiul, Ley, Benedikt, Hossain, Mohammad Sharif, Kibria, Mohammad Golam, Tego, Tedla Teferi, Abate, Dagimawie Tadesse, Weston, Sophie, Karahalios, Amalia, Rajasekhar, Megha, Simpson, Julie A., Rumaseb, Angela, Mnjala, Hellen, Lee, Grant, Anose, Rodas Temesgen, Kidane, Fitsum Getahun, Woyessa, Adugna, Baird, Kevin, Sutanto, Inge, Hailu, Asrat, Price, Ric N. · 2022 · Trials
Cited by 8

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission of the parasite. There is an increased risk of P. vivax parasitaemia following falciparum malaria suggesting a rationale for universal use of radically curative treatment in patients with P. falciparum malaria even in the absence of detectable P. vivax parasitaemia in areas that are co-endemic for both species. Methods: This is a multicentre, health care facility-based, randomized, controlled, open-label trial in Bangladesh, Indonesia and Ethiopia. Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio. Patients are followed up weekly until day 63. The primary endpoint is the incidence risk of any P. vivax parasitemia on day 63. Secondary endpoints include incidence risk on day 63 of symptomatic P. vivax malaria and the risk of any P. falciparum parasitaemia. Secondary safety outcomes include the proportion of adverse events and serious adverse events, the incidence risk of severe anaemia (Hb<5g/dl and <7g/dl) and/or the risk for blood transfusion, the incidence risk of ≥ 25% fall in haemoglobin with and without haemoglobinuria, and the incidence risk of ≥ 25% fall in haemoglobin to under 7g/dl with and without haemoglobinuria. Discussion: This study evaluates the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. If found safe and effective universal radical cure could represent a cost-effective approach to clear otherwise unrecognised P. vivax infections and hence accelerate P. vivax elimination. Trial registration: NCT03916003. Registered on 12 April 2019.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-022-06364-z

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 8

  1. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52(5):612–20. · DOI · Paper page
  2. Hossain MS, Commons RJ, Douglas NM, Thriemer K, Alemayehu BH, Amaratunga C, et al. The risk of plasmodium vivax parasitaemia after P. falciparum malaria: an individual patient data meta-analysis from the WorldWide antimalarial resistance network. PLoS Med. 2020;17(11):e1003393. · DOI
  3. Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on plasmodium vivax recurrence: a WorldWide antimalarial resistance network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18(9):1025–34. · DOI · Paper page
  4. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377. · doi:10.1186/s12936-015-0896-8
  5. Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14(8):e1002379. · DOI · Paper page
  6. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14(5):e1002299. · DOI · Paper page
  7. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394(10202):929–38. · DOI · Paper page
  8. Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, et al. Risk of plasmodium vivax parasitaemia after plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(1):91–101. · DOI

Cited by

See all 8

Metadata

Authors
Thriemer, K., Degaga, T. S., Christian, M., Alam, M. S., Ley, B., Hossain, M. S., Kibria, M. G., Tego, T. T., Abate, D. T., Weston, S., Karahalios, A., Rajasekhar, M., Simpson, J. A., Rumaseb, A., Mnjala, H., Lee, G., Anose, R. T., Kidane, F. G., Woyessa, A., Baird, K., Sutanto, I., Hailu, A., & Price, R. N.
Venue
Trials
Published
2022-05-18
Volume
23
Issue
1
ISSN
1745-6215
Cited by
8
References
1
Language
en
Licence
Funders
  • Australian Academy of Science (Regional Collaborations Program)
  • Bill and Melinda Gates Foundation (INV-010504)
  • National Health and Medical Research Council (APP1132975)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA). https://app.cochat.ai/papers/10.1186/s13063-022-06364-z
The paper
Thriemer, K., Degaga, T. S., Christian, M., Alam, M. S., Ley, B., Hossain, M. S., Kibria, M. G., Tego, T. T., Abate, D. T., Weston, S., Karahalios, A., Rajasekhar, M., Simpson, J. A., Rumaseb, A., Mnjala, H., Lee, G., Anose, R. T., Kidane, F. G., Woyessa, A., . . . Price, R. N. (2022). Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA). Trials. https://doi.org/10.1186/s13063-022-06364-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.